Gilead Sciences (GILD) Acquires MiroBio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Gilead Sciences to Acquire MiroBio
August 4, 2022 8:00 AM EDTAcquisition Provides Gilead with MiroBios Pipeline of Immune Checkpoint Agonists and Proprietary Discovery Platform
MiroBios Scientific Approach to Restoring Immune Balance for the Treatment of Autoimmune Diseases Complements Gileads Inflammation Research and Development Strategy
FOSTER CITY, Calif. & OXFORD, England--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire... More
